AUG 11, 2020 7:48 AM PDT

Supervillain Alert! New Tech IDs Drug-Resistant Superbugs.

WRITTEN BY: Tara Fernandez

The human body is made up of around 10 trillion cells. Fascinatingly, we have 10 times more bacterial cells on our bodies which make up the normal microflora. We are also exposed to a vast number of microbes with pathogenic potential that can on occasion break past immune defenses and wreak havoc. When infection strikes, patients usually provide diagnostic labs with a biological sample for them to determine the identity of the offending bacteria. However, it’s not easy for microbiologists to spot a “supervillain” lurking in the sample. These are antibiotic-resistant superbugs -- pathogens that infect 2 million people in the U.S. and kill at least 23,000 every year.

A team of biomedical engineers at Duke University has invented a new platform for distinguishing the bad guys from the supervillains, using artificial intelligence. Their technology uses machine learning algorithms to pick up subtle differences in the way antibiotic-resistant bacteria grow under laboratory conditions. This would allow microbiologists to flag superbugs in a fraction of the time it currently takes, with a cost-effective and less labor-intensive procedure. Ultimately, this could revolutionize patient outcomes for those infected with these nasty invaders.

Before this breakthrough, diagnostic labs relied heavily on next-generation sequencing to “read” the genes from pathogenic bacteria in search of signature mutations that are known to shield bacteria from the killing effects of antibiotics. However, these techniques are not universally available and it is not always clear how these gene signatures correlate with symptoms or optimal treatment strategies.

Linchong You, the lead author of the study published recently in the Proceedings of the National Academy of Sciences, looked to bacterial growth dynamics instead of genetics for clues.

“We thought that the slight variance in the genes between strains of bacteria might have a subtle effect on their metabolism,” said You.

“But because bacterial growth is exponential, that subtle effect could be amplified enough for us to take advantage of it. To me, that notion is somewhat intuitive, but I was surprised at how well it actually worked.”

The team validated their AI-powered platform using more than 200 strains of bacterial pathogens, many of which were clinically-relevant variants of E. coli. The growth dynamic profiles of these bacteria alone were able to predict a strain’s resistance to antimicrobial drugs  around 75 percent of the time.

According to You, this result is on par or better than standard techniques, including those that rely on genetic sequencing data, adding “And this was just a proof of principle. We believe that with higher-resolution data of the growth dynamics, we could do an even better job in the long term.”

Future plans involve refining the system further such that results can be obtained in under 12 hours.


Sources: Duke Pratt School of Engineering, PNAS.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 03, 2020
Clinical & Molecular DX
Test Diagnoses Dementia While You Sleep by Estimating Your Brain Age
OCT 03, 2020
Test Diagnoses Dementia While You Sleep by Estimating Your Brain Age
Researchers at Harvard have discovered a novel diagnostic marker of dementia for identifying undiagnosed patients or tho ...
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
DEC 01, 2020
Clinical & Molecular DX
Breathing New Life Into COVID Diagnostics
DEC 01, 2020
Breathing New Life Into COVID Diagnostics
Widespread diagnostic testing capacities are an absolutely critical tool for countries battling the pandemic. For now, m ...
DEC 08, 2020
Genetics & Genomics
Advancing Genetic Sequencing with Better Computational Tools
DEC 08, 2020
Advancing Genetic Sequencing with Better Computational Tools
The many advances that have propelled the field of genetics forward have taken a tremendous amount of work in different ...
DEC 15, 2020
Clinical & Molecular DX
Who Should Get the COVID Vaccine First?
DEC 15, 2020
Who Should Get the COVID Vaccine First?
Drug developers’ frantic hunt for vaccines against SARS-CoV-2 has finally begun to bear fruit, with several vaccin ...
JAN 13, 2021
Clinical & Molecular DX
E-Stethoscope Picks up Good (and Bad) Vibrations
JAN 13, 2021
E-Stethoscope Picks up Good (and Bad) Vibrations
A medical device used to survey lung sounds to monitor for signs of respiratory distress has received FDA clearance. RES ...
Loading Comments...